Zosano Pharma and Collaborators to Present Efficacy Data for M207 in the Treatment of Migraine at the 17th Biennial Migraine ...
September 05 2018 - 8:30AM
Zosano Pharma Corporation (NASDAQ:ZSAN) (“Zosano” or the
“Company”), a clinical-stage biopharmaceutical company focused on
providing rapid systemic administration of therapeutics to patients
using its proprietary Adhesive Dermally-Applied Microarray
(“ADAM™”) technology, today announced additional efficacy data will
be presented in a digital poster during the 17th Biennial Migraine
Trust International Symposium (MTIS) to be held from September 6-9,
2018 in London, United Kingdom.
“The selection of our abstract for oral presentation
demonstrates the significant need for new and effective therapies
for patients with difficult to treat migraine,” said lead author
Stewart Tepper M.D., Professor of Neurology, Geisel School of
Medicine at Dartmouth and Director of the Dartmouth Headache Clinic
in Lebanon, New Hampshire. “To date, M207 has shown great potential
in the treatment of traditionally difficult to treat migraine. We
are pleased to have the opportunity to present our data with M207
before the world’s leading experts on migraine and headache.”
Title: |
Efficacy of M207
(Intracutaneous Zolmitriptan) for the Acute Treatment of Difficult
to Treat Migraine |
Presenter: |
Dr. Stewart Tepper |
Abstract
#: |
MTIS2018-063 |
Date: |
Friday, September 7,
2018 |
Time: |
3:20-3:25 PM BST |
Location: |
Hilton London
Metropole, Exhibition Hall (Monarch Suite), Digital Poster Booth
2 |
Further details can be found on the MTIS website at
http://mtis2018.org/.
About M207
M207 is our proprietary formulation of zolmitriptan delivered
utilizing Zosano's proprietary ADAM technology. Zosano's ADAM
technology consists of titanium microprojections (microneedles)
coated with drug, and in the case of M207, our formulation of
zolmitriptan. The drug-coated microneedles penetrate
into the epidermis and dermis, where the drug is dissolved and
enters into the bloodstream. In February 2017, the Company
announced statistically significant results from the ZOTRIP pivotal
study, which demonstrated that the 3.8mg dose of M207 met both
co-primary endpoints, achieving pain freedom and most bothersome
symptom freedom at 2 hours. In November 2017, the
Company announced the initiation of its long-term safety study
evaluating M207 and expects to file an NDA for M207 in the fourth
quarter of 2019.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the timing of expected clinical development milestones, sufficiency
of our capital resources and need for future funding and other
future events and expectations. Readers are urged to consider
statements that include the words "may," "will," "would," "could,"
"should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict
and actual outcomes may differ materially. These include risks and
uncertainties, without limitation, associated with the process of
discovering, developing and commercializing products that are safe
and effective for use as human therapeutics, risks inherent in the
effort to build a business around such products and other risks and
uncertainties described under the heading "Risk Factors" in the
Company's most recent annual report on Form 10-K. Although we
believe that the expectations reflected in these forward-looking
statements are reasonable, we cannot in any way guarantee that the
future results, level of activity, performance or events and
circumstances reflected in forward-looking statements will be
achieved or occur. All forward-looking statements are based on
information currently available to Zosano and Zosano assumes no
obligation to update any such forward-looking statements.
Zosano Contact: John Walker Chief Executive
Officer and Chairman of the Board 510-745-1200
Media Contact:Sara ZelkovicLifeSci Public
Relationssara@lifescipublicrelations.com(646)
876-4933
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Zosano Pharma (NASDAQ:ZSAN)
Historical Stock Chart
From Apr 2023 to Apr 2024